about the author

Amber Tong

amber@endpointsnews.com @AmberTongPW
Amber Tong on LinkedIn

author articles

Janet Wood­cock to be act­ing FDA com­mis­sion­er while Biden team fi­nal­izes nom­i­nee — re­ports

5 years ago
People
FDA+

Covid-19 roundup: Alex­ion's C5 in­hibitor Ul­tomiris miss­es the PhI­II bar; Lon­za in wait­ing game to use in­gre­di­ents in ...

5 years ago
Coronavirus

J&J on track to roll out sin­gle-shot Covid-19 vac­cine in March, Paul Stof­fels con­firms, al­though man­u­fac­tur­ing de­lays ...

5 years ago
Coronavirus

What can a 157-year-old phar­ma gi­ant bring to the ta­ble of cell and gene ther­a­pies? Quite a bit, Bay­er says

5 years ago
Pharma
Cell/Gene Tx

Covid-19 roundup: Re­gen­eron scores $2.6B US sup­ply deal for an­ti­body cock­tail; Brazil­ian re­searchers walk back ...

5 years ago
Coronavirus

Mon­cef Slaoui to step down from Op­er­a­tion Warp Speed in a month — re­port

5 years ago
Coronavirus

Spark co-founder Kathy High joins a long­time col­lab­o­ra­tor at AskBio, help­ing steer Bay­er's gene ther­a­py push

5 years ago
People
Cell/Gene Tx

Mer­ck snags pri­or­i­ty re­view for Pre­vnar 13 ri­val — just one month af­ter Pfiz­er sent its fol­low-on to the FDA

5 years ago
FDA+

Look­ing to leapfrog an­ti­bod­ies and RNAi, Sekar Kathire­san says gene edit­ing ap­proach to cut PC­SK9 looks durable

5 years ago
R&D
Discovery

#JPM21: Resh­ma Ke­wal­ra­mani is on the hunt for 'mid-to late-stage as­sets,' new tools to re­plen­ish Ver­tex pipeline

5 years ago
Deals

Still reel­ing from re­jec­tion, Bio­Marin re­ports a glimpse of those 2-year val­rox da­ta FDA was look­ing for — but is ...

5 years ago
R&D
Cell/Gene Tx

Nas­daq rings in its first biotech IPOs of 2021: a CAR-T spe­cial­ist from Chi­na, a can­cer port­fo­lio play, and a SPAC

5 years ago
Financing
China

DBV re­struc­tur­ing claims 200 jobs as it beats out a path to­ward peanut patch OK

5 years ago
People

Gary Glick, Kei­th Fla­her­ty now have $270M to re­al­ize their vi­sion for Pre­ci­sion On­col­o­gy 2.0 — we'll just have to ...

5 years ago
Financing
Startups

Covid-19 roundup: Cure­Vac finds big vac­cine part­ner in Bay­er; Slaoui will stay on as Biden con­sul­tant

5 years ago
Coronavirus

Au­to­lus buck­les down, chop­ping 20% of staff and seek­ing part­ner for a lead CAR-T pro­gram

5 years ago
People

Covid-19 roundup: EMA rec­om­mends Mod­er­na vac­cine for au­tho­riza­tion; Wood­cock re­turns to FDA as Hahn ad­vi­sor — ...

5 years ago
Coronavirus

Edg­ing to­ward a piv­otal read­out, Bio­gen picks a new dis­cov­ery part­ner for oph­thalmic gene ther­a­py

5 years ago
Deals

News brief­ing: Mar­ius sub­mits NDA for oral hy­pog­o­nadism ther­a­py; Cell­tri­on's bil­lion­aire founder steps down

5 years ago
News Briefing

Can a new pro­tein bring RNA drugs where they can't reach? J&J vet Sue Dil­lon's Io­n­is-part­nered biotech gets $88M to ...

5 years ago
Financing

Lynn Seely hits the ex­it as My­ovant grad­u­ates to com­mer­cial space — hand­ing the reins to Am­gen vet

5 years ago
People

Slammed with PhII flop for lead drug, Calithera lays off a third of its staffers

5 years ago
R&D

As­traZeneca/Ox­ford score first vote of con­fi­dence as UK au­tho­rizes their Covid-19 vac­cine

5 years ago
FDA+
Coronavirus

Covid-19 roundup: Mod­er­na of­fers vac­cine to work­ers, con­trac­tors and board mem­bers; Claim­ing 79% vac­cine ef­fi­ca­cy, ...

5 years ago
Coronavirus
First page Previous page 58596061626364 Next page Last page
A service from the Financial Times